ERBB2 and anemia: During nab-PTX with anti-HER2 therapy, grade 3 hematological toxicities included neutropenia (23.3%), leukopenia (7.0%), FN (4.7%), anemia (2.3%), and liver dysfunction (7.0%); while grade 3 non-hematological toxicities included peripheral sensory neuropathy (4.7%), arthralgia (2.3%), myalgia (2.3%), and diarrhea (4.7%).